TFome technology, advanced through Blavatnik Biomedical Accelerator, may contribute to new cell therapies

Harvard’s ARMMs technology to be commercialized by Vesigen Therapeutics for targeted intracellular delivery of large-molecule drugs

Genetically programmed, living hydrogel material facilitates intestinal wound healing and may lead to a therapy for patients with inflammatory bowel disease

Accelerator-funded research points to potential therapy for heightened touch sensitivity in autism spectrum disorders